Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of shareholding changes rather than a financial performance report.
Material Changes
The filing details increases in the notional interests of seven PDMRs in GSK Ordinary Shares. These changes resulted from the re-investment of dividends paid on April 14, 2016, under the GlaxoSmithKline Deferred Investment Award Programme. The transaction price was 1494.50 pence per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the specific number of Ordinary Shares acquired by each PDMR listed in the filing.
- Confirm the dividend payment date of April 14, 2016, and the associated reinvestment price of 1494.50 pence.
- Review the full list of PDMRs involved: Mr R G Connor, Mr S A Hussain, Mr D S Redfern, Ms C Thomas, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.